Company performance
Current Price
as of Jan 07, 2025$41.20
P/E Ratio
N/A
Market Cap
$3.06B
- SWTX
Description
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Metrics
Overview
- HQStamford, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerSWTX
- Price$41.2+6.02%
Trading Information
- Market cap$3.06B
- Float88.57%
- Average Daily Volume (1m)1,132,078
- Average Daily Volume (3m)1,152,937
- EPS-$3.73
Company
- Revenue$135.49M
- Rev growth (1yr)N/A
- Net income-$53.53M
- Gross margin91.44%
- EBITDA margin-115.74%
- EBITDA-$57.06M
- EV$2.01B
- EV/Revenue14.83
- P/EN/A
- P/S22.58
- P/B5.75
Documents
SEC Filings
Factset Street Account